Was a big bargin below $4.
Forecast suggests ongoing OCF and NPAT growth.
In this COVID environment where everyone is downgrading or withdrawing guidance we have a solid pharmaceutical company with growing sales and a good portfolio of a patented product, an orphan drug and a range of generics which doing well in the Australiasian space.
Furthermore, their sales overseas are co-ordinated by pharmaceuticals already known in the respective regions so no need to try and form a name for themselves.
Ann: Maxigesic IV licensed in six new European nations, page-4
Add to My Watchlist
What is My Watchlist?
